| Overall Survival | Progression-Free Survival | ||||
Parameter | HR | P | 95% CI | HR | P | 95% CI |
dNLR ≥ 3 | 5.41 | 0.001 | 2.01 - 14.56 | 2.29 | 0.027 | 1.10 - 4.79 |
Age | 0.96 | 0.113 | 0.92 - 1.01 | 0.99 | 0.496 | 0.96 - 1.02 |
Sex | 0.94 | 0.879 | 0.40 - 2.18 | 0.92 | 0.809 | 0.46 - 1.84 |
Race | 0.56 | 0.222 | 0.22 - 1.42 | 0.89 | 0.729 | 0.47 - 1.68 |
Smoking | 0.38 | 0.002 | 0.20 - 0.70 | 0.73 | 0.195 | 0.46 - 1.17 |
Treatment line | 1.41 | 0.115 | 0.92 - 2.16 | 1.45 | 0.024 | 1.05 - 1.99 |
ECOG PS | 1.79 | 0.031 | 1.06 - 3.05 | 1.50 | 0.062 | 0.98 - 2.30 |
Liver metastases | 4.46 | 0.005 | 1.58 - 12.61 | 1.76 | 0.162 | 0.80 - 3.90 |
Brain metastases | 0.57 | 0.378 | 0.17 - 1.97 | 0.89 | 0.809 | 0.36 - 2.21 |
Bone metastases | 2.10 | 0.088 | 0.90 - 4.93 | 1.23 | 0.55 | 0.62 - 2.46 |
Squamous histology | 5.58 | 0.001 | 2.06 - 15.14 | 1.74 | 0.106 | 0.89 - 3.40 |